A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Condition:   Metastatic Breast Cancer Interventions:   Drug: Abemaciclib;   Drug: Nonsteroidal Aromatase Inhibitor (NSAI) Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

ConclusionsAmong breast cancer patients, nearly one-third exhibit clinical-pathological stage discordance. This high likelihood of discordance is important to consider for counseling and treatment planning.
Source: The American Journal of Surgery - Category: Surgery Source Type: research
yong-Huey Lai Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge. Palbociclib—a selective inhibitor of cyclin-dependent kinases (CDK) 4/6—has therapeutic potential against estrogen receptor (ER)-positive and HER2-negative breast cancer. However, the question as to whether it can be clinically useful in endometrial cancer remains open. Here, we show that combined treatment with palbociclib and megesterol acet...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
A trial presented at ASCO 2019 found HER2 heterogenity can impact response rates to some treatments in HER2-positive breast cancer patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Oncogene, Published online: 19 July 2019; doi:10.1038/s41388-019-0893-4FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Residual nodal disease after NAC analysed by LNRC or LNR = 0.25 cut-off value, is prognostic and can discriminate between favourable and unfavourable outcomes for TNBC and Her2+ breast cancers.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Condition:   HER2-positive Early Breast Cancer Interventions:   Drug: Pertuzumab IV;   Drug: Trastuzumab IV;   Drug: FDC of Pertuzumab and Trastuzumab SC;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Procedure: Surgery;   Radiation: Post-Operative Radiotherapy;   Drug: Hormone Therapy Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: 16 July 2019Source: Cell Reports, Volume 28, Issue 3Author(s): Pavel Bouchal, Olga T. Schubert, Jakub Faktor, Lenka Capkova, Hana Imrichova, Karolina Zoufalova, Vendula Paralova, Roman Hrstka, Yansheng Liu, Holger Alexander Ebhardt, Eva Budinska, Rudolf Nenutil, Ruedi AebersoldSummaryAccurate classification of breast tumors is vital for patient management decisions and enables more precise cancer treatment. Here, we present a quantitative proteotyping approach based on sequential windowed acquisition of all theoretical fragment ion spectra (SWATH) mass spectrometry and establish key proteins for breast tu...
Source: Cell Reports - Category: Cytology Source Type: research
HER2 (human epidermal growth factor receptor 2) is a protein that is associated with some particularly aggressive forms of breast cancer. The presence of high concentrations of this protein seems to lead to the growth of tumors, so inactivating HER2 ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Ob/Gyn Oncology Source Type: blogs
CONCLUSIONS: Adjuvant trastuzumab has substantially improved the survival of patients with HER2+ eBC, contributing over 41,000 LYG to Spanish society (over 36,000 DFLYG) in a cost-effective manner. However, the sum of LYG with trastuzumab is still far from the LY estimated for the general population, supporting the need of further advances in HER2+ eBC. PMID: 31303965 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Research | Study